“…Accelerated partial-breast irradiation (APBI) with interstitial pulsed-dose-rate (PDR) or high-dose-rate (HDR) brachytherapy regimens recently became a field of much interest in radiooncologic research [12,14,21,22]. Data from quality-assured phase II trials increasingly underlined the safety and efficacy of this treatment approach for a highly selected subgroup of breast cancer patients with a genuine low risk of local recurrence [2,3,9,16,17,20,23].…”